Showing results (301-310 of 351) with videos related to

Sort By:
Pageof 36
Biorxiv : the Preprint Server for Biology|April 2, 2024
Mapping single-cell developmental potential in health and disease with interpretable deep learningMinji Kang, Jose Juan Almagro Armenteros, Gunsagar S Gulati, et al.
Molecular Cancer|March 13, 2022
Tumorigenic circulating tumor cells from xenograft mouse models of non-metastatic NSCLC patients reveal distinct single cell heterogeneity and drug responsesKanve N Suvilesh, Yulia I Nussbaum, Vijay Radhakrishnan, et al.
NPJ Precision Oncology|July 4, 2026
Integrated multiclass driver ctDNA profiling enables MPNST detection and monitoring in NF1 patientsPaul A Jones, Aaron U Bektas, Jeffrey J Szymanski, et al.
Research Square|November 19, 2025
Integrated Multiclass Driver ctDNA Profiling Enables MPNST Detection and Monitoring in NF1 PatientsPaul A Jones, Aaron U Bektas, Jeffrey J Szymanski, et al.
JCO Precision Oncology|September 9, 2020
Cell-free DNA alterations in the AR enhancer and locus predict resistance to AR-directed therapy in patients with metastatic prostate cancerHa X Dang, Pradeep S Chauhan, Haley Ellis, et al.
Cancer Treatment Reviews|April 16, 2025
Current and future directions in theranostics for neuroendocrine prostate cancerGokce Belge Bilgin, Fabrice Lucien-Matteoni, Aadel A Chaudhuri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2019
Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable AlterationsSiddhartha Devarakonda, Sumithra Sankararaman, Brett H Herzog, et al.
Oncogene|June 25, 2013
Annexin A2 depletion delays EGFR endocytic trafficking via cofilin activation and enhances EGFR signaling and metastasis formationM de Graauw, L Cao, L Winkel, et al.
JTO Clinical and Research Reports|November 24, 2025
Safety and Efficacy of Sequential Chemoimmunotherapy Followed by Concurrent Chemoradiation in Unresectable Stage III NSCLCArthi Sridhar, Aditi Singh, Scott Hansen, et al.
European Journal of Cancer (Oxford, England : 1990)|April 15, 2014
Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient ProgrammeF Khan, C Ottensmeier, S Popat, et al.
Pageof 36